PATENT CLAIM ANALYSIS

Application Number: 16001322
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["514", "001000"]

Abstract:
The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and/or different CYP2D6 metabolizer status.

Claim (Index 1):
A method of treating a psychiatric disorder in a patient, comprising:\n (a) administering vortioxetine; then (b) stopping the administration of vortioxetine; and (c) administering a first dose of an MAOI at least 24 days after step (b); wherein the psychiatric disorder is selected from the group consisting of depression, major depressive disorder, pre-menstrual dysphoric disorder, acute depressive episodes with bipolar I, treatment resistant depression, general anxiety disorder, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, bulimia nervosa, cognitive dysfunction in pre-menstrual dysphoric disorder, attention deficit hyperactivity disorder, attention deficit hyperactivity disorder in adult patients, and combinations thereof, and wherein the patient has at least one of the following characteristics:\n (i) BMI of at least about 35; \n (ii) % IBW of at least about 150%; \n (iii) waist size greater than about 42 inches; \n (iv) % body fat greater than about 40%; \n (v) % android body fat greater than about 40%; \n (vi) % gynoid body fat greater than about 40%; \n (vii) total body fat greater than about 40 kg; \n (viii) intermediate CYP2D6 metabolizer; or \n (ix) poor CYP2D6 metabolizer.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 94.0
- Lexical Diversity: 1.68254
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15838944', '15596585', '14034727', '11576178', '15636238']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6900745278544519
- 35 USC 102 Novelty (BERT): 0.618076380474713
- Combined Prediction Score: 0.6828747131164781
- Mean Citation Score: 267.782782
- Max Citation Score: 560.754
- Similarity Product: 492.8066444360018

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test